Serum Cytokine Profile in Adalimumab-treated Refractory Uveitis Patients: Decreased IL-22 Correlates with Clinical Responses

References

• Whitcup S. (2010). Diagnostic testing. In: Nussenblatt R, Whitcup S. (eds.), Uveitis: Fundamentals and Clinical Practice, 4th ed. (pp. 60–71). New York: Mosby-Elsevier
   Google Scholar
• Tervo T, van Setten GB, Hovi M, et al. C-reactive protein serum levels in patients with ocular disease. Acta Ophthalmol (Copenh). 1994;72:110–113
   Google Scholar
• de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum. 2009;61:1484–1490
   PubMed Web of Science ®Google Scholar
• Horai R, Caspi RR. Cytokines in autoimmune uveitis. J Interferon Cytokine Res. 2011;31:733–744
   PubMed Web of Science ®Google Scholar
• Sugita S, Takase H, Taguchi C, Mochizuki M. The role of soluble TNF receptors for TNF-α in uveitis. Invest Ophthalmol Vis Sci. 2007;48:3246–3252
   PubMed Web of Science ®Google Scholar
• Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol. 2001;132:794–796
   PubMed Web of Science ®Google Scholar
• Curnow SJ, Falciani F, Durrani OM, et al. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profile in uveitis. Invest Ophthalmol Vis Sci. 2005;46:4251–4259
   PubMed Web of Science ®Google Scholar
• Pérez VL, Papaliodis GN, Chu D, et al. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm. 2004;12:193–201
   PubMed Web of Science ®Google Scholar
• Sagawa K, Ito K, Sakaguchi M. Production of IL-8 and the other cytokines by T cell clones established from the ocular fluid of patients with Behcet’s disease. Ocul Immunol Inflamm. 1995;3:63–71
   Google Scholar
• el-Shabrawi Y, Livir-Rallatos C, Christen W, et al. High levels of interleukin-12 in aqueous and vitreous of patients with uveitis patients. Ophthalmology. 1998;105:1659–1663
   Google Scholar
• Kuiper JJ, Mutis T, de Jager W, et al. Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy. Am J Ophthalmol. 2011;152:177–182
   PubMed Web of Science ®Google Scholar
• Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173–1175
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251–255
   PubMed Web of Science ®Google Scholar
• Kramer M, Monselise Y, Bahar I, et al. Serum cytokine levels in active uveitis and remission. Curr Eye Res. 2007;32:669–675
   PubMed Web of Science ®Google Scholar
• Klok AM, Luyendijk L, Zaal MJ, et al. Elevated serum IL-8 levels are associated with disease activity in idiopathic intermediate uveitis. Br J Ophthalmol. 1998;82:871–874
   PubMed Web of Science ®Google Scholar
• Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008;49:3058–3064
   PubMed Web of Science ®Google Scholar
• Li F, Yang P, Liu X, et al. Upregulation of interleukin 21 and promotion of interleukin 17 production in chronic or recurrent Vogt-Koyanagi-Harada disease. Arch Ophthalmol. 2010;128:1449–1454
   PubMedGoogle Scholar
• Jiang S, Liu X, Luo L, et al. Elevated serum IL-23 correlates with intraocular inflammation after cataract surgery in patients with Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2010;94:1078–1082
   Google Scholar
• Takase H, Futagami Y, Yoshida T, et al. Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis. Invest Ophthalmol Vis Sci. 2006;47:15557–1561
   Google Scholar
• Dick AD, Forrester JV, Liversidge J, et al. Role of TNFα in experimental autoimmune uveitis. Prog Retin Eye Res. 2004;23:617–637
   PubMed Web of Science ®Google Scholar
• Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: anti-TNF-alpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm. 2009;17:403–414
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. 2009;127:819–822
   PubMed Web of Science ®Google Scholar
• Sugita S, Yamada Y, Kaneko S, et al. Induction of regulatory T cells by infliximab in Behçet's disease. Invest Ophthalmol Vis Sci. 2011;52:476–484
   PubMed Web of Science ®Google Scholar
• Calleja S, Cordero-Coma M, Rodriguez E, et al. Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(−) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study. Eye (Lond). 2012;26:468–477
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516
   PubMed Web of Science ®Google Scholar
• Charles P, Elliot MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF alpha therapy in rheumatoid arthritis. J Immunol. 1999;163:1521–1528
   PubMed Web of Science ®Google Scholar
• Mastroianni A, Minutilli E, Mussi A, et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol. 2005;153:531–536
   PubMed Web of Science ®Google Scholar
• Martinez-Borra J, Lopez-Larrea C, González S, et al. High serum tumor necrosis factor alfa levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Gastroenterology. 2002;97:2350–2356
   Google Scholar
• Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheumatism. 2004;50:3161–3169
   PubMed Web of Science ®Google Scholar
• Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009;29:210–214
   PubMed Web of Science ®Google Scholar
• da Rocha LF Jr, Duarte AL, Dantas AT, et al. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. J Rheumatol. 2012;39: 1320–1325
   PubMed Web of Science ®Google Scholar
• Ke Y, Sun D, Jiang G, et al. IL-22-induced regulatory CD11b APC suppress experimental autoimmune uveitis. J Immunol. 2011;187:2130–2139
   PubMedGoogle Scholar
• Li Z, Liu B, Maminishkis A, et al. Gene expression profiling in autoimmune noninfectious uveitis disease. J Immunol. 2008;181:5147–5157
   PubMed Web of Science ®Google Scholar
• Liang SC, Nickerson-Nutter C, Pittman DD, et al. IL-22 induces an acute-phase response. J Immunol. 2010;185:5531–5538
   PubMed Web of Science ®Google Scholar